Cargando…

Improving patient outcomes in pulmonary hypertension

The updated management of PAH patients is leading to improvements in quality of life and outcome http://ow.ly/TAvMf

Detalles Bibliográficos
Autores principales:	Galiè, Nazzareno, McLaughlin, Vallerie V., Rubin, Lewis J., Simonneau, Gérald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487624/ https://www.ncbi.nlm.nih.gov/pubmed/26621969 http://dx.doi.org/10.1183/16000617.0064-2015

Ejemplares similares

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
por: Matthews, Jennifer Cowger, et al.
Publicado: (2008)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018)

Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts
por: Vachiéry, Jean-Luc, et al.
Publicado: (2019)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Pulmonary Hypertension: Types and Treatments
por: Rose-Jones, Lisa J, et al.
Publicado: (2015)

Pulmonary Arterial Hypertension: Combination Therapy in Practice
por: Burks, Marsha, et al.
Publicado: (2018)

Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States
por: Cascino, Thomas M., et al.
Publicado: (2020)

Barriers to physical activity in patients with pulmonary hypertension
por: Cascino, Thomas M., et al.
Publicado: (2019)

Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension
por: Visovatti, Scott H., et al.
Publicado: (2012)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
por: Galiè, Nazzareno, et al.
Publicado: (2010)

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2013)

Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
por: Palazzini, Massimiliano, et al.
Publicado: (2023)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

The revised definition of pulmonary hypertension: exploring the impact on patient management
por: Simonneau, Gérald, et al.
Publicado: (2019)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

The pathophysiology of chronic thromboembolic pulmonary hypertension
por: Simonneau, Gérald, et al.
Publicado: (2017)

The changing landscape of chronic thromboembolic pulmonary hypertension management
por: Madani, Michael, et al.
Publicado: (2017)

Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4f5pqshrvqmo5me2tbbpblr95